Intratumoral heterogeneity of HER-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray

被引：40

作者：

Shin, Sandra J. ^{[1
]}

Hyjek, Elizabeth ^{[1
]}

Early, Erin ^{[1
]}

Knowles, Daniel M. ^{[1
]}

机构：

[1] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA

来源：

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY | 2006年 / 14卷 / 04期

关键词：

HER-2/neu; gene amplification; intratumoral heterogeneity;

D O I：

10.1177/1066896906293055

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Fluorescence in-situ hybridization is increasingly being used to determine HER-2/neu status in patients with breast carcinoma. The possibility that intratumoral heterogeneity of HER-2/neu gene amplification may potentially contribute to inaccurate assessment of HER-2/neu status was investigated in routine cases of invasive mammary carcinomas. From 169 representative formalin-fixed, paraffin-embedded blocks of invasive duct mammary carcinomas with grade 3 architecture, 48 cases were analyzed by fluorescence in-situ hybridization and 59 analyses were performed. Intratumoral heterogeneity for HEB-2/neu gene amplification was demonstrated in only 5 (16%) of 31 cases where morphologically similar areas of a single tumor were analyzed. We conclude from this study that intratumoral heterogeneity of HER-2/neu gene amplification is a demonstrable but relatively uncommon occurrence. For invasive mammary carcinomas, the accurate assessment of HER-2/neu status by fluorescence in-situ hybridization analysis is not significantly confounded by intratumoral heterogeneity of HER-2/neu gene amplification in individual tumors.

引用

页码：279 / 284

页数：6

共 39 条

[1]

Andersson J, 2004, APPL IMMUNOHISTO M M, V12, P14

[2] Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization [J].

Aubele, M ;

Mattis, A ;

Zitzelsberger, H ;

Walch, A ;

Kremer, M ;

Hutzler, P ;

Höfler, H ;

Werner, M .

CANCER GENETICS AND CYTOGENETICS, 1999, 110 (02) :94-102

[3]

BERGER MS, 1988, CANCER RES, V48, P1238

[4] c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases [J].

Carlomagno, C ;

Perrone, F ;

Gallo, C ;

DeLaurentiis, M ;

Lauria, R ;

Morabito, A ;

Pettinato, G ;

Panico, L ;

DAntonio, A ;

Bianco, AR ;

DePlacido, S .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2702-2708

[5] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[6] Genetic instability of cancer cells is proportional to their degree of aneuploidy [J].

Duesberg, P ;

Rausch, C ;

Rasnick, D ;

Hehlmann, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (23) :13692-13697

[7] Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab [J].

Dybdal, N ;

Leiberman, G ;

Anderson, S ;

McCune, B ;

Bajamonde, A ;

Cohen, RL ;

Mass, RD ;

Sanders, C ;

Press, MF .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) :3-11

[8]

EDGARTON SE, 2000, BREAST CANC RES TREA, V64, P55

[9] A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].

FEARON, ER ;

VOGELSTEIN, B .

CELL, 1990, 61 (05) :759-767

[10]

Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966

← 1 2 3 4 →